免疫治疗基础治疗后行细胞减积性肾切除术治疗转移性肾细胞癌：病例系列及文献复习。
Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.
机构信息
Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA.
Center for Urologic Oncology, Glickman Urologic & Kidney Institute, Cleveland Clinic, Cleveland, OH 44106, USA.
出版信息
Curr Oncol. 2021 May 20;28(3):1921-1926. doi: 10.3390/curroncol28030178.
The role and timing of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving immunotherapy-based regimens is unclear. However, the ability to achieve a complete response for metastatic renal cell carcinoma likely requires a nephrectomy at some point during treatment. Here we present a case series of three patients with metastatic clear-cell renal-cell carcinoma who received front-line immunotherapy-based treatment and subsequently underwent a cytoreductive nephrectomy. All three patients had a complete response to therapy and have subsequently remained off systemic therapy for a median of 531 days (range, 476-602). We also review the limited literature in this setting and highlight ongoing clinical trials. Although the role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving immunotherapy-based treatment is uncertain, a subset of patients will benefit from either an immediate or deferred cytoreductive nephrectomy. Ongoing trials are underway to further determine how to incorporate cytoreductive nephrectomy into the treatment paradigm for patients with metastatic renal cell carcinoma.
细胞减灭性肾切除术在接受免疫治疗方案的转移性肾细胞癌患者中的作用和时机尚不清楚。然而，对于转移性肾细胞癌来说，要实现完全缓解，可能需要在治疗过程中的某个时候进行肾切除术。在这里，我们报告了三例接受一线免疫治疗方案治疗后接受细胞减灭性肾切除术的转移性透明细胞肾细胞癌患者的病例系列。所有三名患者对治疗均有完全缓解，并且随后中位无全身性治疗时间为 531 天（范围为 476-602）。我们还回顾了该治疗环境中的有限文献，并强调了正在进行的临床试验。尽管细胞减灭性肾切除术在接受免疫治疗方案治疗的转移性肾细胞癌患者中的作用尚不确定，但有一部分患者将受益于即刻或延迟的细胞减灭性肾切除术。正在进行的试验旨在进一步确定如何将细胞减灭性肾切除术纳入转移性肾细胞癌患者的治疗方案。
Zotero 插件